Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.

Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, Devasia T, Al-Hawaray M, Cho CS, Nathan H, Maybaum J, Zalupski MM, Lawrence TS.

J Clin Oncol. 2019 Aug 9:JCO1900730. doi: 10.1200/JCO.19.00730. [Epub ahead of print]

PMID:
31398082
2.

Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.

Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, Parsels LA, Shi J, Ramnath N, Wahl DR, Pasca di Magliano M, Frankel TL, Kryczek I, Lei YL, Lawrence TS, Zou W, Morgan MA.

Cancer Res. 2019 Aug 1;79(15):3940-3951. doi: 10.1158/0008-5472.CAN-19-0761. Epub 2019 May 17.

PMID:
31101760
3.

The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.

Parsels LA, Parsels JD, Tanska DM, Maybaum J, Lawrence TS, Morgan MA.

Cell Cycle. 2018;17(9):1076-1086. doi: 10.1080/15384101.2018.1475827. Epub 2018 Jul 18.

4.

PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.

Parsels LA, Karnak D, Parsels JD, Zhang Q, Vélez-Padilla J, Reichert ZR, Wahl DR, Maybaum J, O'Connor MJ, Lawrence TS, Morgan MA.

Mol Cancer Res. 2018 Feb;16(2):222-232. doi: 10.1158/1541-7786.MCR-17-0455. Epub 2017 Nov 13.

5.

Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.

Parsels LA, Tanska DM, Parsels JD, Zabludoff SD, Cuneo KC, Lawrence TS, Maybaum J, Morgan MA.

Cell Cycle. 2016;15(5):730-9. doi: 10.1080/15384101.2016.1148841.

6.

Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.

Kausar T, Schreiber JS, Karnak D, Parsels LA, Parsels JD, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA.

Neoplasia. 2015 Oct;17(10):757-66. doi: 10.1016/j.neo.2015.09.006.

7.

Targeting mcl-1 for radiosensitization of pancreatic cancers.

Wei D, Zhang Q, Schreiber JS, Parsels LA, Abulwerdi FA, Kausar T, Lawrence TS, Sun Y, Nikolovska-Coleska Z, Morgan MA.

Transl Oncol. 2015 Feb;8(1):47-54. doi: 10.1016/j.tranon.2014.12.004.

8.

Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.

Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA.

Clin Cancer Res. 2014 Oct 1;20(19):5085-96. doi: 10.1158/1078-0432.CCR-14-1038. Epub 2014 Aug 12.

9.

Improving the efficacy of chemoradiation with targeted agents.

Morgan MA, Parsels LA, Maybaum J, Lawrence TS.

Cancer Discov. 2014 Mar;4(3):280-91. doi: 10.1158/2159-8290.CD-13-0337. Epub 2014 Feb 18. Review.

10.

Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.

Engelke CG, Parsels LA, Qian Y, Zhang Q, Karnak D, Robertson JR, Tanska DM, Wei D, Davis MA, Parsels JD, Zhao L, Greenson JK, Lawrence TS, Maybaum J, Morgan MA.

Clin Cancer Res. 2013 Aug 15;19(16):4412-21. doi: 10.1158/1078-0432.CCR-12-3748. Epub 2013 Jun 26.

11.

Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair.

Wei D, Parsels LA, Karnak D, Davis MA, Parsels JD, Marsh AC, Zhao L, Maybaum J, Lawrence TS, Sun Y, Morgan MA.

Clin Cancer Res. 2013 Aug 15;19(16):4422-32. doi: 10.1158/1078-0432.CCR-13-0788. Epub 2013 Jun 18.

12.

Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.

Venkatesha VA, Parsels LA, Parsels JD, Zhao L, Zabludoff SD, Simeone DM, Maybaum J, Lawrence TS, Morgan MA.

Neoplasia. 2012 Jun;14(6):519-25.

13.

Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.

Vance S, Liu E, Zhao L, Parsels JD, Parsels LA, Brown JL, Maybaum J, Lawrence TS, Morgan MA.

Cell Cycle. 2011 Dec 15;10(24):4321-9. doi: 10.4161/cc.10.24.18661. Epub 2011 Dec 15.

14.

Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.

Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, Morosini D, Brown JL, Zabludoff SD, Maybaum J, Lawrence TS, Morgan MA.

Clin Cancer Res. 2011 Jun 1;17(11):3706-15. doi: 10.1158/1078-0432.CCR-10-3082. Epub 2011 Apr 11.

15.

Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments.

Zhao L, Morgan MA, Parsels LA, Maybaum J, Lawrence TS, Normolle D.

Clin Cancer Res. 2011 Mar 1;17(5):1057-64. doi: 10.1158/1078-0432.CCR-10-1935. Epub 2010 Dec 3.

16.

Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Maybaum J, Lawrence TS.

Cancer Res. 2010 Jun 15;70(12):4972-81. doi: 10.1158/0008-5472.CAN-09-3573. Epub 2010 May 25.

17.

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.

Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, Maybaum J.

Mol Cancer Ther. 2009 Jan;8(1):45-54. doi: 10.1158/1535-7163.MCT-08-0662.

18.

Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Morgan MA, Parsels LA, Maybaum J, Lawrence TS.

Clin Cancer Res. 2008 Nov 1;14(21):6744-50. doi: 10.1158/1078-0432.CCR-08-1032. Review.

19.

The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.

Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS.

Clin Cancer Res. 2008 Aug 15;14(16):5142-9. doi: 10.1158/1078-0432.CCR-07-4072.

20.

The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.

Morgan MA, Parsels LA, Parsels JD, Lawrence TS, Maybaum J.

Cell Cycle. 2006 Sep;5(17):1983-8. Epub 2006 Sep 1.

PMID:
16931916
21.

Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.

Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, Lawrence TS.

Cancer Res. 2005 Aug 1;65(15):6835-42.

22.
23.
24.

Characterization of a cis-acting regulatory element in the protein coding region of thymidylate synthase mRNA.

Lin X, Parsels LA, Voeller DM, Allegra CJ, Maley GF, Maley F, Chu E.

Nucleic Acids Res. 2000 Mar 15;28(6):1381-9.

25.

N-Nitrosodimethylamine-mediated cytotoxicity in a cell line expressing P450 2E1: evidence for apoptotic cell death.

Lin HL, Parsels LA, Maybaum J, Hollenberg PF.

Toxicol Appl Pharmacol. 1999 Jun 1;157(2):117-24.

PMID:
10366544
26.

The role for translational control of the cell cycle.

Parsels LA, Chu E.

Cancer J Sci Am. 1998 Sep-Oct;4(5):287-95. Review. No abstract available.

PMID:
9815290
27.

Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells.

Parsels LA, Parsels JD, Wagner LM, Loney TL, Radany EH, Maybaum J.

Cancer Chemother Pharmacol. 1998;42(5):357-62.

28.

Prevention of fluorodeoxyuridine-induced cytotoxicity and DNA damage in HT29 colon carcinoma cells by conditional expression of wild-type p53 phenotype.

Parsels LA, Zellars RC, Loney TL, Parsels JD, Clarke MF, Merchant AK, Lawrence TS, Maybaum J.

Mol Pharmacol. 1997 Oct;52(4):600-5.

PMID:
9380022
29.
30.

Supplemental Content

Loading ...
Support Center